Rhinomed adds material boost to distribution
Scott Power
Morgans
Rhinomed (RNO, Add, Price Target A$0.06) Following last month’s announcement that RNO signed with Symbion to distribute its innovative snoring product Mute, they have announced another large distribution partner in Australia in signing Sigma Pharmaceuticals, bringing a further 1,200 pharmacies to the table. This deal will effectively double the number of pharmacies stocking the product in Australia. With these signings, we are expecting a material pickup in 4Q revenues as sales of Mute compliment the growing base for the Turbines. We have not made any changes to our forecasts and maintain our Add recommendation and price target of A$0.06 Report attached
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media.
I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these sectors, which help with identification of key trends and developments.
1 stock mentioned
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
Why "buy and manage" is the better way to invest in stocks
Livewire Markets
